A significant attribute of biologic therapeutics is extremely high target binding specificity. The RuiYi technology enables the Company to leverage biologic therapeutic specificity across a select set of targets from a large family of proteins, the G-Protein Coupled Receptor (GPCR) protein family, where specificity in binding is very important.
G-Protein Coupled Receptors (GPCRs) have been a valuable class of targets for therapeutic intervention with approximately 30% of today's approved drugs modulating these proteins. Many GPCRs still provide incredible promise as therapeutic targets; however, their similarity with other GPCRs have made finding selective small molecule modulators very difficult. While there has been limited success in discovering antibody modulators to GPCRs, their transmembrane specific conformation has proven classical techniques difficult. RuiYi has developed a series of technologies that enable the purified, isolated, conformationally correct presentation of functional GPCRs, termed intermembranous Conformation Antigen Presenting System or iCAPS, optimized for generation of antibodies and other biologics.